Hsp90 Inhibitor-Evodiamine Conjugates for Colon Cancer Therapy

A series of heat shock protein 90 (Hsp90) inhibitor-evodiamine conjugates were rationally designed for colon cancer therapy. The dataset includes in vitro antiproliferative activity (IC50 = 7.7 nM) and in vivo tumor growth inhibition data for conjugate 5a. It was authored by Yuhang Sun and last updated on 2026-05-28.

Use Cases

• Evaluate structure-activity relationships for Hsp90 inhibitor-natural product conjugates based on the described series.
• Assess in vivo antitumor efficacy of oral drug candidates based on reported tumor growth inhibition percentages.
• Compare endocytosis-mediated delivery strategies for natural product derivatives based on the eHsp90 targeting mechanism.

Strengths

• Includes specific potency metrics, such as an in vitro IC50 of 7.7 nM.
• Reports in vivo efficacy results, including a 72.9% tumor growth inhibition rate upon intraperitoneal injection.
• Data is associated with a specific research project on rational drug design.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The dataset is small in scale (193.2 KB), indicating limited scope.

Provenance

Source

figshare

Collection Method

Rationally designed and tested as part of a drug discovery project.

Freshness

Last updated 2026-05-28 19:45:27; freshness should be verified.